SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus oncology pipeline, particularly the FDA-cleared expansion of its REGAIN glioblastoma trial and upcoming clinical updates, alongside completed enrollment in its pancreatic-cancer IMPACT study. Traders are broadly bullish on the catalyst pipeline, though some are waiting for larger-cohort data to confirm the early results.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results, particularly resilient parks performance and improving streaming profitability, have reinforced bullish sentiment and prompted analyst upgrades. Traders remain divided, with some seeing a turnaround while others point to the stocks long stretch of weak, range-bound performance.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is pulling back after a strong run as traders position ahead of earnings, with some wary of recent SaaS-sector weakness and the stocks valuation. Others remain bullish on growth and AI-driven commerce, while security concerns appear in some bearish posts but are not the dominant discussion.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias early third-quarter report and raised full-year revenue guidance are driving attention, with continued LUPKYNIS sales growth supporting the results. Traders are split between viewing the report as solid execution and frustration that the shares fell despite it, compounded by confusion over whether management held an earnings call.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned Q4 BLA submission for CAN-2409 in localized prostate cancer and upcoming SITC pipeline data. Bulls see the clinical and regulatory milestones as potential catalysts, while skeptics point to the steep decline, CEO share sales, limited transparency, possible dilution and uncertainty about filing timing; some also blame broader biotech weakness and thin trading.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys shares are drawing attention after a sharp post-earnings rally despite revenue and EPS misses; traders are focusing on premium subscriber growth, stronger gross margin, and an upbeat fourth-quarter profit outlook. The move has surprised some investors, who question why the stock rose on a mixed report, while bulls see the guidance and improving ad revenue as the more important signals.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak fourth-quarter outlook after earnings, amid softer PC demand and manufacturing constraints, triggered a steep selloff and analyst downgrades. Traders are divided between calling the decline an overreaction and buying the dip, and seeing it as evidence of deeper execution and turnaround problems.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could weaken in 2027 has sparked concerns about pricing and CorMedixs largest revenue driver, contributing to a sharp selloff. Traders are divided over the impact: some see a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMS reimbursement estimates as a reason the reaction may be excessive.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is drawing attention amid a sharp pullback alongside other AI and semiconductor stocks, with traders citing stretched valuations, broad market pressure, and uncertainty ahead of earnings. The community is split between buyers treating the decline as an opportunity and bears warning that the stock remains overvalued and could fall further.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is drawing attention around its monthly distribution and ex-dividend schedule as Nasdaq weakness weighs on the ETF. Traders are focused on the income and buying the dip, while others note that its covered-call strategy can cushionbut not preventlosses and may limit upside in a rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Snowflake (SNOW) Down 4.1% Since Last Earnings Report?

Snowflake (SNOW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gitlab (GTLB) Down 4.7% Since Last Earnings Report: Can It Rebound?

Gitlab (GTLB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GitLab CFO's Stake Drops by Over 30,000 Shares Worth $1.6 Million After the Stock Hit a 52-Week High

Key PointsThe transaction involved 32,628 shares with a total value of ~$1.6 million as of September 16, 2026...

GitLab (GTLB) Reports Net ARR Growth Above 40% as Operating Cash Flow Turns Negative. Will AI Demand Convert Into Durable Revenue and Cash?

GitLab (GTLB) Reports Net ARR Growth Above 40% as Operating Cash Flow Turns Negative. Will AI Demand Convert Into Durable Revenue and Cash...

GitLab (GTLB) Q2 2027 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

GitLab Is Starting to Prove the Bears Wrong

Key PointsGitLab turned in a strong quarter and upped its guidance...

Why GitLab Stock Surged This Week

Key PointsGitLab's sales and earnings in fiscal Q2 exceeded Wall Street's forecasts...

Dow Jumps Around 300 Points Ahead Of Jobs Report: Investor Sentiment Improves, But Fear & Greed Index Remains In 'Fear' Zone

U.S. stocks rose as Fear & Greed improved to 33, while war tensions lifted oil. NVIDIA, GitLab and Dell surged on deal and earnings news.read more...

Why Did PFE, GTLB, COP Stocks Jump To 52-Week Highs Today?

Equity

Pfizer, GitLab, and Conoco Phillips shares surged to 52-week highs on Wednesday amid a series of positive company catalysts and optimistic Wall Street coverage. 

Why GitLab Stock Jumped Today

Key PointsGitLab's adjusted profits topped Wall Street's expectations...

GitLab, Inc. engages in the intelligent development, security, and operations (DevSecOps) platform for software innovation. It enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Bullish Sentiment

<ul><li>PFE stock closed up 1.65% amid growing optimism for its vaccine pipelines.&nbsp;</li><li>GTLB stock gained nearly 10% at close on Wednesday on strong fiscal second-quarter results and Wall Street price-target hikes.</li><li>COP stock closed up 0.74% as rising oil prices amid the ongoing conflict in the Strait of Hormuz bolstered energy stocks higher.&nbsp;</li></ul>Shares of Pfizer Inc. (PFE), GitLab Inc. (GTLB) and ConocoPhillips (COP) surged to 52-week highs on Wednesday amid a series of positive company catalysts and Wall Street optimism.&nbsp;<a href="https://stocktwits.com/symbol/PFE">PFE stock</a> closed up 1.65% higher amid growing optimism for its vaccine pipelines after the U.S. Food and Drug Administration cleared its updated COVID-19 vaccine.&nbsp;<a href="https://stocktwits.com/symbol/GTLB">GTLB stock</a> gained nearly 10% at close on Wednesday as strong fiscal second-quarter (Q2) results, coupled with Wall Street price target hikes, boosted share prices.&nbsp;<a href="https://stocktwits.com/symbol/COP">COP stock</a> closed up 0.74% as rising oil prices amid the ongoing conflict in the Strait of Hormuz supported its better performance.&nbsp;<h2 class="st-heading-2">Pfizer’s Vaccine Pipeline Optimism Boosts Stock Price</h2>PFE stock jumped to a fresh 52-week high of $29.09 on Wednesday, clocking three straight sessions of climbs.&nbsp;Pfizer’s recent momentum has been supported by several positive developments. The FDA approved Pfizer and BioNTech’s updated 2026–2027 COVID-19 vaccine for the upcoming fall respiratory season, giving the companies an early foothold in the market.&nbsp;Pfizer and Valneva also reported encouraging Phase 3 results for their Lyme disease vaccine candidate, which demonstrated more than 70% efficacy.&nbsp;Meanwhile, Pfizer posted second-quarter revenue of $15.03 billion and adjusted earnings per share of $0.77, leading management to raise its full-year 2026 revenue outlook. The stock has also benefited from a broader rotation into defensive sectors, including healthcare, as investors navigate wider market uncertainty.Retail sentiment around PFE stock was ‘neutral’ at the time of writing. The stock has risen more than 15% in 2026.&nbsp;<h2 class="st-heading-2">Gitlab Jumps On Strong Quarterly Results</h2>GTLB stock surged to a 52-week high of $55.55, putting it on track for its second consecutive week of gains after it posted strong Q2&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-gtlb-stock-surging-nearly-21-premarket-today/cZsAZdXRJuk">results</a>.&nbsp;GitLab generated $286.3 million in revenue, a rise of 21% year-on-year, and about five percentage points above its guidance. Net annual recurring revenue increased 42%, marking the company’s second-best growth quarter in four years. CFO Jessica Ross described the quarter as an important turning point for the business.&nbsp;The company also received a series of price target hikes from Wall Street analysts, with Canaccord according it the highest target.&nbsp;Analyst Kingsley Crane raised the price target on GitLab to $70 from $40 and maintained a ‘Buy’ rating on the shares, noting that Q2 was the strongest quarter of GitLab's transition and that it likes the setup here for one of the most important software development assets on the planet, just now beginning to see an inflection in consumption traction.In Q2, GitLab recorded the strongest quarter for new customer orders in three years, with the number of first-time orders more than doubling from a year earlier.&nbsp;Truist, UBS, RBC Capital were among other analysts that raised their targets on GTLB stock.&nbsp;Retail sentiment on Stocktwits around the company’s shares was ‘extremely bullish’ at the time of writing. GTLB stock is up about 37% so far this year.&nbsp;<h2 class="st-heading-2">ConocoPhillips Rises On Higher Oil Prices</h2>COP stock surged to a fresh annual high of $137.37 on Wednesday, after clocking two consecutive months of gains in July and August, as tensions in the Middle East have pushed oil prices higher.&nbsp;The ongoing conflict between the U.S. and Iran and the supply constraint due to the blockage of the Strait of Hormuz pushed Brent crude prices to over $95 a barrel in recent days.&nbsp;Meanwhile, Seaport Research initiated coverage of Conoco Phillips with a ‘Neutral’ rating and no price target.&nbsp;As per Koyfin data, the stock has a 12-month average price target of $145.33, implying an upside of nearly 6% from its last close.&nbsp;Retail sentiment on Stocktwits around the company’s shares was ‘neutral’ at the time of writing. COP stock is up nearly 42% so far this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer, GitLab, and Conoco Phillips shares surged to 52-week highs on Wednesday amid a series of positive company catalysts and optimistic Wall Street coverage.

Conoco Phillips

Gitlab Inc

Pfizer Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$54.09
Prev Close	$56.65
Open	$56.03
Dividend Yield	0.00%
50-Day Moving Average	$50.09
Beta	1.51
Avg. Volume	5.81M
PE Ratio	-173.14

52-Week High	$58.01
52-Week Low	$18.73
Market Capitalization	$9.01B
EPS (Annual)	-$0.3355
Price to Book	9.78
Revenue Per Employee	$370,241.86

Feed

News

Sentiment

Earnings

Fundamentals

Info

GTLB Fundamentals